Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Does Current Portuguese Financing Model for Multiple Sclerosis Covers for Estimated Needs?
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
Quantitative Susceptibility Mapping Indicates a Disturbed Brain Iron Homeostasis in Neuromyelitis Optica - A Pilot Study.
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.
Information processing speed in multiple sclerosis: Past, present, and future.
ERβ in CD4+ T Cells Is Crucial for Ligand-Mediated Suppression of Central Nervous System Autoimmunity.
Improving Clinical Outcomes and Health Care Resources Utilization in Multiple Sclerosis: A Portuguese Hospital Perspective.
The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Mucocele After Orbital Fracture Repair Masquerading as Optic Neuritis.
Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study.
All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
Difficulties in adjustment to multiple sclerosis: vulnerability and unpredictability of illness in the foreground.
An Economic Evaluation of Subcutaneous and Intramuscular Interferon Beta-1a in Multiple Sclerosis Using a Direct Head-To-Head Study.
Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.
The Impact of Adherence and Development of Neutralizing Antibodies to Interferons β on Treatment of Multiple Sclerosis in the Czech Republic.
Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Chronic pain disrupts the reward circuitry in multiple sclerosis.
Optic neuritis as a presenting symptom of Mycoplasma pneumoniae infection.
Systematic Review and Critique of Health Economic Models on Relapsing-Remitting Multiple Sclerosis in the UK.
[The biological role of sulfatides].
A fatal mycotic sepsis after retrograde intrarenal surgery: a case report and literature review.
Using a Panel Survey to Identify Predictors of Disease-Modifying Drug Adherence in Patients with Multiple Sclerosis.
Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis.
Working Ability and Monetarily Valued Productivity of Patients with Multiple Sclerosis Treated with Natalizumab.
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »